133 related articles for article (PubMed ID: 36965903)
1. Maximize the safety and efficacy of fertility preservation by random start/dual ovarian stimulation for early breast cancer patients.
Young SR; Chang YE; Yang WV; Lu BJ; Chou SY; Chen CH
Taiwan J Obstet Gynecol; 2023 Mar; 62(2):330-333. PubMed ID: 36965903
[TBL] [Abstract][Full Text] [Related]
2. The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review.
Rodgers RJ; Reid GD; Koch J; Deans R; Ledger WL; Friedlander M; Gilchrist RB; Walters KA; Abbott JA
Hum Reprod; 2017 May; 32(5):1033-1045. PubMed ID: 28333356
[TBL] [Abstract][Full Text] [Related]
3. Two cases of polycystic ovary syndrome with onset of severe ovarian hyperstimulation syndrome following controlled ovarian stimulation with aromatase inhibitors for fertility preservation before breast cancer treatment.
Oishi S; Mekaru K; Nakamura R; Miyagi M; Akamine K; Heshiki C; Aoki Y
Taiwan J Obstet Gynecol; 2021 Sep; 60(5):931-934. PubMed ID: 34507678
[TBL] [Abstract][Full Text] [Related]
4. Random-start controlled ovarian hyperstimulation with letrozole for fertility preservation in cancer patients: case series and review of literature.
Keskin U; Ercan CM; Yilmaz A; Babacan A; Korkmaz C; Duru NK; Ergun A
J Pak Med Assoc; 2014 Jul; 64(7):830-2. PubMed ID: 25255597
[TBL] [Abstract][Full Text] [Related]
5. Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies.
Meirow D; Raanani H; Maman E; Paluch-Shimon S; Shapira M; Cohen Y; Kuchuk I; Hourvitz A; Levron J; Mozer-Mendel M; Brengauz M; Biderman H; Manela D; Catane R; Dor J; Orvieto R; Kaufman B
Fertil Steril; 2014 Aug; 102(2):488-495.e3. PubMed ID: 24934489
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Oocyte and Embryo Quality Between Random Start and Controlled Ovarian Stimulation Cycles in Cancer Patients Undergoing Fertility Preservation.
İsrafilova G; Şükür YE; Özkavukcu S; Sönmezer MA; Atabekoğlu CS; Özmen B; Berker B; Aytaç R; Koç A; Sönmezer M
Reprod Sci; 2021 Aug; 28(8):2200-2207. PubMed ID: 33409878
[TBL] [Abstract][Full Text] [Related]
7. The effect of aromatase inhibitor on controlled ovarian stimulation for oocyte cryopreservation in adolescent and young cancer patients.
Suzuki R; Horage-Okutsu Y; Kawahara T; Nakamura K; Shiraishi E; Iwahata H; Suzuki-Takahashi Y; Sugishita Y; Takae S; Suzuki N
J Obstet Gynaecol Res; 2023 Mar; 49(3):973-979. PubMed ID: 36606606
[TBL] [Abstract][Full Text] [Related]
8. Random Start Ovarian Stimulation for Oocyte or Embryo Cryopreservation in Women Desiring Fertility Preservation Prior to Gonadotoxic Cancer Therapy.
Danis RB; Pereira N; Elias RT
Curr Pharm Biotechnol; 2017 Nov; 18(8):609-613. PubMed ID: 28786354
[TBL] [Abstract][Full Text] [Related]
9. COH outcomes in breast cancer patients for fertility preservation: a comparison with the expected response by age.
Malacarne E; Devesa M; Martinez F; Rodriguez I; Coroleu B
J Assist Reprod Genet; 2020 Dec; 37(12):3069-3076. PubMed ID: 32945994
[TBL] [Abstract][Full Text] [Related]
10. Letrozole-associated controlled ovarian hyperstimulation in breast cancer patients versus conventional controlled ovarian hyperstimulation in infertile patients: assessment of oocyte quality related biomarkers.
Goldrat O; Van Den Steen G; Gonzalez-Merino E; Dechène J; Gervy C; Delbaere A; Devreker F; De Maertelaer V; Demeestere I
Reprod Biol Endocrinol; 2019 Jan; 17(1):3. PubMed ID: 30606204
[TBL] [Abstract][Full Text] [Related]
11. Use of Aromatase Inhibitors in IVF for Fertility Preservation of Non-Breast Cancer Patients: A Case Series.
Ben-Haroush A; Ben-Aharon I; Lande Y; Fisch B
Isr Med Assoc J; 2018 Mar; 20(3):145-146. PubMed ID: 29527850
[TBL] [Abstract][Full Text] [Related]
12. Fertility preservation for women with breast cancer: a multicentre randomized controlled trial on various ovarian stimulation protocols.
Balkenende EME; Dahhan T; Beerendonk CCM; Fleischer K; Stoop D; Bos AME; Lambalk CB; Schats R; Smeenk JMJ; Louwé LA; Cantineau AEP; de Bruin JP; Linn SC; van der Veen F; van Wely M; Goddijn M
Hum Reprod; 2022 Jul; 37(8):1786-1794. PubMed ID: 35776109
[TBL] [Abstract][Full Text] [Related]
13. Aromatase Inhibitors for Ovarian Stimulation in Patients with Breast Cancer.
Ferreiro E; de Uralde BL; Abreu R; García-Velasco JA; Muñoz E
Curr Drug Targets; 2020; 21(9):910-921. PubMed ID: 32077823
[TBL] [Abstract][Full Text] [Related]
14. Stimulation of the ovaries in women with breast cancer undergoing fertility preservation: Alternative versus standard stimulation protocols; the study protocol of the STIM-trial.
Dahhan T; Balkenende EME; Beerendonk CCM; Fleischer K; Stoop D; Bos AME; Lambalk CB; Schats R; van Golde RJT; Schipper I; Louwé LA; Cantineau AEP; Smeenk JMJ; de Bruin JP; Reddy N; Kopeika Y; van der Veen F; van Wely M; Linn SC; Goddijn M
Contemp Clin Trials; 2017 Oct; 61():96-100. PubMed ID: 28710053
[TBL] [Abstract][Full Text] [Related]
15. The case for aromatase inhibitors use in oncofertility patients. Should aromatase inhibitors be combined with gonadotropin treatment in breast cancer patients undergoing ovarian stimulation for fertility preservation prior to chemotherapy? A debate.
Fatum M; McVeigh E; Child T
Hum Fertil (Camb); 2013 Dec; 16(4):235-40. PubMed ID: 23863119
[TBL] [Abstract][Full Text] [Related]
16. Progesterone levels in letrozole associated controlled ovarian stimulation for fertility preservation in breast cancer patients.
Goldrat O; Gervy C; Englert Y; Delbaere A; Demeestere I
Hum Reprod; 2015 Sep; 30(9):2184-9. PubMed ID: 26109617
[TBL] [Abstract][Full Text] [Related]
17. Response to ovarian stimulation is not impacted by a breast cancer diagnosis.
Quinn MM; Cakmak H; Letourneau JM; Cedars MI; Rosen MP
Hum Reprod; 2017 Mar; 32(3):568-574. PubMed ID: 28122888
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of random-start progestin-primed ovarian stimulation for fertility preservation.
Huang H; Itaya Y; Samejima K; Ichinose S; Narita T; Matsunaga S; Saitoh M; Takai Y
J Ovarian Res; 2022 Jan; 15(1):2. PubMed ID: 34983605
[TBL] [Abstract][Full Text] [Related]
19. The use of GnRH-agonist trigger for the final maturation of oocytes in normal and low responders undergoing planned oocyte cryopreservation.
Maslow BL; Guarnaccia M; Stefanacci C; Ramirez L; Klein JU
Hum Reprod; 2020 May; 35(5):1054-1060. PubMed ID: 32406915
[TBL] [Abstract][Full Text] [Related]
20. Effective method for emergency fertility preservation: random-start controlled ovarian stimulation.
Cakmak H; Katz A; Cedars MI; Rosen MP
Fertil Steril; 2013 Dec; 100(6):1673-80. PubMed ID: 23987516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
